Literature DB >> 2394122

Effect of hyperbaric oxygen on murine neutrophil and T-lymphocyte functions.

M A Gadd1, D S McClellan, T S Neuman, J F Hansbrough.   

Abstract

We investigated the effect of repeated hyperbaric oxygen (HBO) exposure on PMN and T-lymphocyte functions in a murine model. Animals received eight 90-min exposures twice daily to 2.4 ata and 100% or 10% oxygen. Control animals were maintained in room air. On the ninth day spleens and peritoneal cell exudates were harvested. Phagocytosis was measured by flow-cytometric analysis of the ability of PMN to engulf formalin-killed, fluorescence-labeled Staphylococcus aureus. PMN-killing capacity was measured by the ability of PMN to undergo an oxidative burst after stimulation with N-formyl methionyl-leucyl-phenylalanine, phorbol myristate, or opsonized zymosan. T-lymphocyte subpopulations were identified using monoclonal antibodies and two-color flow cytometry after 48 h stimulation with phytohemagglutinin, and lymphocyte proliferation was measured by 3 H-thymidine incorporation. We found PMN phagocytosis and oxidative burst were unchanged after HBO treatment. Lymphocyte proliferation was decreased, and an activated population of CD8+ T cells appeared after mitogen stimulation. We conclude that, although PMN function is not affected by prior HBO, lymphocyte proliferation is decreased.

Entities:  

Mesh:

Year:  1990        PMID: 2394122     DOI: 10.1097/00003246-199009000-00014

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

1.  Hyperbaric oxygen therapy and liver transplantation.

Authors:  Vijayaragavan Muralidharan; Chris Christophi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 2.  Hyperbaric Oxygen Therapy-A Novel Treatment Modality in Oral Submucous Fibrosis: A Review.

Authors:  M Ashwini Kumar; Besta Radhika; Nishanth Gollamudi; Satya Prakash Reddy; Uday Shankar Yaga
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 3.  [Postoperative and bacterial osteitis. New possibilities for therapy].

Authors:  V Heppert; U Glatzel; A Wentzensen
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

4.  Exposure to hyperbaric oxygen induces tumour necrosis factor-alpha (TNF-alpha) secretion from rat macrophages.

Authors:  N Lahat; H Bitterman; N Yaniv; A Kinarty; N Bitterman
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

5.  Hyperbaric oxygen therapy reduces severity and improves survival in severe acute pancreatitis.

Authors:  Mehrdad Nikfarjam; Christine M Cuthbertson; Caterina Malcontenti-Wilson; Vijayaragavan Muralidharan; Ian Millar; Christopher Christophi
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

6.  Hyperbaric oxygen therapy as a sole agent is not immunosuppressant in a highly immunogenic mouse model.

Authors:  Adam Gassas; Weixian Min; A Wayne Evans; Susan Carter; George K Sándor; Eyal Grunebaum
Journal:  Bone Marrow Res       Date:  2010-08-03

7.  Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients.

Authors:  Giuliano Vezzani; Silvia Quartesan; Pasqua Cancellara; Enrico Camporesi; Devanand Mangar; Thomas Bernasek; Prachiti Dalvi; Zhongjin Yang; Antonio Paoli; Alex Rizzato; Gerardo Bosco
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 8.  Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis.

Authors:  Christian Johann Lerche; Franziska Schwartz; Mia Marie Pries-Heje; Emil Loldrup Fosbøl; Kasper Iversen; Peter Østrup Jensen; Niels Høiby; Ole Hyldegaard; Henning Bundgaard; Claus Moser
Journal:  Front Cell Infect Microbiol       Date:  2022-02-03       Impact factor: 5.293

9.  Hyperbaric oxygen prevents early death caused by experimental cerebral malaria.

Authors:  Yara C Blanco; Alessandro S Farias; Uta Goelnitz; Stefanie C P Lopes; Wagner W Arrais-Silva; Bruna O Carvalho; Rogério Amino; Gerhard Wunderlich; Leonilda M B Santos; Selma Giorgio; Fabio T M Costa
Journal:  PLoS One       Date:  2008-09-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.